Results 61 to 70 of about 15,183 (185)
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice [PDF]
, 2018 Concurrent use of bisphosphonate therapy reduces the anabolic effect of teriparatide. Consequently, in clinical practice bisphosphonates are discontinued and teriparatide therapy held for a few months to allow bone turnover to increase.
Keel, Christina +4 more
core
Treatment Trade‐Offs and Choices for Femoral Fractures: A Systematic Review and Meta‐Analysis
Orthopaedic Surgery, Volume 17, Issue 5, Page 1298-1313, May 2025.This review examines the trade‐offs between surgical intervention and traction therapy for adult and elderly patients with femoral fractures and surgical contraindications, particularly in resource‐limited settings. While intramedullary nailing may offer better clinical outcomes, traction therapy is often preferred due to limited surgical resources ...
Jiarui Li +11 more
wiley +1 more source
Bone biology in aging periodontal and peri‐implant tissues
Periodontology 2000, EarlyView.Abstract Background Periodontal disease is an age‐related chronic inflammatory condition leading to tooth loss. Dental implants are an option for replacement of lost teeth in older adults. However, age‐related changes to alveolar bone may have pathological implications for its role in supporting the dentition and dental implants.
Dalia Rasheed Issa +2 more
wiley +1 more source
First Generic Teriparatide: Structural and Biological Sameness to Its Reference Medicinal Product
PharmaceuticsTeriparatide is an anabolic peptide drug indicated for the treatment of osteoporosis. Recombinant teriparatide was first approved in 2002 and has since been followed by patent-free alternatives under biosimilar or hybrid regulatory application.
Jimena Fernández-Carneado +11 more
doaj +1 more source
PLoS ONE, 2020 BackgroundGiving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion ...
Shih-Hao Cheng +3 more
doaj +1 more source
Teriparatide treatment in severe osteoporosis – a controlled 10-year follow-up study
BMC Musculoskeletal Disorders, 2022 Background Teriparatide was the first anabolic agent recommended for the treatment of osteoporosis. Long-term real-world, controlled studies are not available.
Georgios Kontogeorgos +4 more
doaj +1 more source
Experimental Physiology, EarlyView.Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu +4 more
wiley +1 more source
Osteoporosis and Sarcopenia, 2018 Objectives: As clinics that treat patients with osteoporosis do not usually have central dual-energy X-ray absorptiometry (DXA), bone density is often measured with radial DXA.
Harumi Nakayama +2 more
doaj +1 more source
BMC Musculoskeletal Disorders, 2021 Background Revisions are mainly caused by wear debris-induced aseptic loosening. How to effectively suppress debris-induced periprosthetic osteolysis has become an urgent problem.
Peng Wang +5 more
doaj +1 more source
Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation [PDF]
, 2017 Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical
Blunn, G +5 more
core +1 more source